Diagnose Early Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Diagnose Early's estimated annual revenue is currently $7.1M per year.(i)
  • Diagnose Early's estimated revenue per employee is $155,000

Employee Data

  • Diagnose Early has 46 Employees.(i)
  • Diagnose Early grew their employee count by 35% last year.

Diagnose Early's People

NameTitleEmail/Phone
1
Chief Technology OfficerReveal Email/Phone
2
Director IT & Security | CISOReveal Email/Phone
3
Director IT & SecurityReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.4M70-8%$53MN/A
#2
$32.4M167-26%$110MN/A
#3
$0.9M60%N/AN/A
#4
$2.8M1813%N/AN/A
#5
$0.8M5-50%N/AN/A
#6
$0.8M100%N/AN/A
#7
$14M90-12%N/AN/A
#8
$0.4M33610%$236.7MN/A
#9
$4.8M62-74%$160MN/A
#10
$3.7M24-8%N/AN/A
Add Company

What Is Diagnose Early?

Founded by a Nobel Prize-winning team including Stanford M.D./Ph.D., Nobel Laureate, and a Harvard Business School/UW Madison Engineer. We are commercializing diagnostics for Cancer, Neurological, and Infectious Diseases, and are in clinical trials at Stanford University. The Diagnose Early team has patented a COVID-19 Acuity test titled D.E.C.A. that uses amino acid biomarkers found in breath to accurately and non-invasively predict the clinical course of each patient and therefore guide treatment.

keywords:N/A

N/A

Total Funding

46

Number of Employees

$7.1M

Revenue (est)

35%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$6.6M4615%N/A
#2
$3.5M4624%N/A
#3
$9.2M462%N/A
#4
$9.9M460%N/A
#5
$5.5M4768%N/A